1,971 reports of this reaction
1.6% of all INSULIN ASPART reports
#10 most reported adverse reaction
OFF LABEL USE is the #10 most commonly reported adverse reaction for INSULIN ASPART, manufactured by Novo Nordisk. There are 1,971 FDA adverse event reports linking INSULIN ASPART to OFF LABEL USE. This represents approximately 1.6% of all 120,218 adverse event reports for this drug.
Patients taking INSULIN ASPART who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for INSULIN ASPART, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for INSULIN ASPART:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,971 FDA reports for INSULIN ASPART. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 1.6% of all adverse event reports for INSULIN ASPART, making it a notable side effect.
If you experience off label use while taking INSULIN ASPART, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.